JP2013505268A5 - - Google Patents

Download PDF

Info

Publication number
JP2013505268A5
JP2013505268A5 JP2012529971A JP2012529971A JP2013505268A5 JP 2013505268 A5 JP2013505268 A5 JP 2013505268A5 JP 2012529971 A JP2012529971 A JP 2012529971A JP 2012529971 A JP2012529971 A JP 2012529971A JP 2013505268 A5 JP2013505268 A5 JP 2013505268A5
Authority
JP
Japan
Prior art keywords
tumor
sparc
antibody
sms
mammal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012529971A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013505268A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/049545 external-priority patent/WO2011035274A1/en
Publication of JP2013505268A publication Critical patent/JP2013505268A/ja
Publication of JP2013505268A5 publication Critical patent/JP2013505268A5/ja
Pending legal-status Critical Current

Links

JP2012529971A 2009-09-18 2010-09-20 癌の治療におけるsparc微小環境シグネチャの使用 Pending JP2013505268A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27696909P 2009-09-18 2009-09-18
US61/276,969 2009-09-18
PCT/US2010/049545 WO2011035274A1 (en) 2009-09-18 2010-09-20 Use of the sparc microenvironment signature in the treatment of cancer

Publications (2)

Publication Number Publication Date
JP2013505268A JP2013505268A (ja) 2013-02-14
JP2013505268A5 true JP2013505268A5 (cg-RX-API-DMAC7.html) 2013-11-07

Family

ID=43759058

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012529971A Pending JP2013505268A (ja) 2009-09-18 2010-09-20 癌の治療におけるsparc微小環境シグネチャの使用

Country Status (13)

Country Link
US (1) US20120245089A1 (cg-RX-API-DMAC7.html)
EP (1) EP2478362B1 (cg-RX-API-DMAC7.html)
JP (1) JP2013505268A (cg-RX-API-DMAC7.html)
KR (1) KR20120092597A (cg-RX-API-DMAC7.html)
CN (1) CN102576016A (cg-RX-API-DMAC7.html)
AU (1) AU2010295324B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012008316A2 (cg-RX-API-DMAC7.html)
CA (1) CA2774550A1 (cg-RX-API-DMAC7.html)
IL (1) IL218642A0 (cg-RX-API-DMAC7.html)
MX (1) MX2012003287A (cg-RX-API-DMAC7.html)
NZ (1) NZ598801A (cg-RX-API-DMAC7.html)
WO (1) WO2011035274A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201202657B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8383358B2 (en) * 2009-05-28 2013-02-26 Abraxis Bioscience, Llc Use of 2 anti-SPARC antibodies to predict response to melanoma chemotherapy
AU2011261240A1 (en) * 2010-06-03 2013-01-10 Abraxis Bioscience, Llc Use of the SPARC microenvironment signature in the treatment of cancer
EP3539080B1 (en) * 2016-11-10 2022-03-23 F. Hoffmann-La Roche AG Distance-based tumor classification

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5003621A (en) 1989-11-02 1991-03-26 Motorola, Inc. Direct conversion FM receiver
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
WO2004085621A2 (en) * 2003-03-20 2004-10-07 Dana-Farber Cancer Institute, Inc. Gene expression in breast cancer
ATE511550T1 (de) * 2003-07-17 2011-06-15 Pacific Edge Biotechnology Ltd Marker zum nachweis von magenkrebs
JP4682152B2 (ja) * 2003-12-31 2011-05-11 ザ・ペン・ステート・リサーチ・ファンデーション 卵巣がんの化学療法に対する抵抗性を予測および克服するための方法ならびに結腸がんの発生を予測するための方法
AU2006249235B2 (en) * 2004-05-14 2010-11-11 Abraxis Bioscience, Llc Sparc and methods of use thereof
GB0417740D0 (en) * 2004-08-10 2004-09-08 Uc3 Methods and kit for the prognosis of breast cancer
AU2005297303B2 (en) * 2004-10-19 2011-11-10 Lsip, Llc Novel diagnostic kit for malignant melanoma
CN103169729A (zh) * 2005-02-18 2013-06-26 阿布拉科斯生物科学有限公司 治疗剂的组合和给予方式以及联合治疗
WO2006112930A2 (en) * 2005-02-18 2006-10-26 Abraxis Bioscience, Inc. Q3 sparc deletion mutant and uses thereof
RU2451521C2 (ru) * 2006-06-16 2012-05-27 Онкотерапи Сайенс, Инк. Sparc-производные антигенные пептиды отторжения опухоли и лекарственные средства, содержащие их
US9675578B2 (en) * 2006-12-14 2017-06-13 Abraxis Bioscience, Llc Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
AU2008226283A1 (en) * 2007-03-09 2008-09-18 The University Of British Columbia Assessing chemotherapy resistance of colorectal tumors by determining sparc hypermethylation
CN101678078B (zh) * 2007-04-13 2014-12-10 阿布拉西斯生物科学公司 Sparc及其使用方法
AU2008260447B2 (en) * 2007-06-01 2013-10-10 Abraxis Bioscience, Llc Methods and compositions for treating recurrent cancer

Similar Documents

Publication Publication Date Title
Colombo et al. HER2 targeting as a two-sided strategy for breast cancer diagnosis and treatment: Outlook and recent implications in nanomedical approaches
EP2531598A4 (en) WHSC1 AND WHSC1L1 FOR TARGET GENES TO CANCER THERAPY AND DIAGNOSIS
Ren et al. LINC00941 promotes progression of non-small cell lung cancer by sponging miR-877-3p to regulate VEGFA expression
Liu et al. The siRNA cocktail targeting VEGF and HER2 inhibition on the proliferation and induced apoptosis of gastric cancer cell
Bian et al. RETRACTED ARTICLE: Circular RNA CircCDYL Regulates Proliferation and Apoptosis in Non-Small Cell Lung Cancer Cells by Sponging miR-185-5p and Upregulating TNRC6A
Bao et al. Aberrant expression of SPAG6 and NM23 predicts poor prognosis of human osteosarcoma
RU2013119459A (ru) Комплекс ipp в качестве маркера лечения эрлотинибом
Iyevleva et al. EP209 miR-190b-5p expression is a highly reliable discriminator between ER-positive and ER-negative breast cancer
Uy et al. Case report: Alveolar rhabdomyosarcoma of the prostate presenting as lower urinary tract symptoms in a Young Adult
Akdemir et al. NIRL-11 3D-FSE IMAGING FOR RADIOSURGERY PLANNING IMPROVES BRAIN METASTASIS DETECTION AND REDUCES INTRACRANIAL RELAPSE
Colleoni IN2 Debate: The biology of breast cancer in young women is unique–In favour
Ronsley et al. NCOG-73. EFFECT OF TIME TO DIAGNOSIS IN CHILDREN WITH MALIGNANT CENTRAL NERVOUS SYSTEM TUMORS ON SURVIVAL OUTCOMES AND DISEASE-ASSOCIATED MORBIDITY: AN INSTITUTIONAL COHORT STUDY
Xue et al. VGLL4 inhibits stemness and cisplatin resistance in non-small cell lung cancer via the COL3A1/NF-κB pathway
Kokkali et al. EP210 Invasive lobular carcinoma with extracellular mucin production. Presentation of the second case diagnosed within three years in our hospital
Ivanova et al. NVTG-03 IDENTIFYING THE DRIVERS OF EARLY BRAIN METASTASES ESTABLISHMENT IN BREAST CANCER PATIENTS
Mao et al. Long Non-Coding RNA Small Nucleolar RNA Host Gene 1 and MicroRNA-100-3p Expression in Endometrial Carcinoma and Its Effect on the Proliferation and Apoptosis of Ishikawa Cells
Dhanani et al. NCOG-72. DIFFERENTIAL EFFECTS OF SURGERY AND CHEMOTHERAPY ON CHILDREN WITH POSTERIOR FOSSA BRAIN TUMORS
Cluxton IN1 YSC–Young Survival Coalition
Chao et al. Jia-Hong Chen1, 2, Wen-Chien Huang3, 4, Oluwaseun Adebayo Bamodu5, 6, Peter Mu-Hsin Chang7, 8
Hirai et al. The role of PD-L1 in a high-grade invasive human oral squamous cell carcinoma microenvironment
Carlson AACR Annual Meeting: More Research Linking MicroRNAs to Malignancy, Metastasis
Schwartzberg The old and the new
Naselli et al. Reply from Authors re: Maurizio Brausi. Are New Technologies for Detection and Treatment of Non–Muscle-Invasive Bladder Cancer (NMIBC) So Important? A Plea For Adoption by Teaching Programs to Improve Results After Standard White Light Transurethral Resection of NMIBC. Eur Urol 2012; 61: 914–6: New Technologies May Really Improve Non–muscle-invasive Bladder Cancer Management: Now Try Them!
Hesdorffer et al. ES 03.04 Mesothelioma: Beyond the Basics
Belldegrun Panel Discussion: What the Urologist Should Know About Targeted Treatments for Renal Cancer.